← All trials
NCT06287606
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 29, 2023
- Primary completion
- Jan 4, 2024
- Completion date
- Jan 4, 2024
- First posted
- Mar 1, 2024
- Last posted
- Nov 29, 2024
- Enrollment
- 161
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taejoon Pharm Co., Ltd.Lead sponsor
- Kyung Hee UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.